Journalartikel

Jahr der Veröffentlichung: 2012

Seiten: 1263-1269

Zeitschrift: Clinical Chemistry and Laboratory Medicine

Bandnummer: 50

Heftnummer: 7

ISSN: 1434-6621

Open Access Status: Bronze

DOI Link: https://doi.org/10.1515/cclm-2011-0644

Verlag: De Gruyter

Abstract: 
Therapeutic antibodies are an important part of Biopharmaceuticals. They are highly innovative and specifi c drugs. Additionally, they play a challenging role in new demands in diagnostics because they disturb conventional antibody-based tests, such as immunoassays. The recovery ELISA is a newly developed immunoassay technology for monitoring such therapeutic antibodies or comparable biologics during the therapy. The recovery ELISA determines three results in one test: the free level of antigen (if available in serum), the level of therapeutic antibody and the specifi c dose-response interaction. The free level of antigen is the amount that can be measured in the immunoassay, as it exists unmasked under assay conditions. The relationship between therapeutic antibody level and neutralization rate of target protein is shown by the so-called 'recovery curve'. The recovery ELISA is demonstrated with the example of Omalizumab/IgE.

Harvard-Zitierstil: Strohner, P., Staatz, A., Sarrach, D., Steiss, J. and Becher, G. (2012) The recoveryELISA - a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy, Clinical Chemistry and Laboratory Medicine, 50(7), pp. 1263-1269. https://doi.org/10.1515/cclm-2011-0644

APA-Zitierstil: Strohner, P., Staatz, A., Sarrach, D., Steiss, J., & Becher, G. (2012). The recoveryELISA - a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clinical Chemistry and Laboratory Medicine. 50(7), 1263-1269. https://doi.org/10.1515/cclm-2011-0644